
This scientific paper presents the ACHIEVE-1 trial, a phase 3 study investigating orforglipron, an oral, nonpeptide GLP-1 receptor agonist, for treating type 2 diabetes. The research evaluates its efficacy and safety as a once-daily monotherapy in adults whose type 2 diabetes is managed solely through diet and exercise. The findings demonstrate that orforglipron significantly reduces glycated hemoglobin levels and promotes body weight reduction over a 40-week period, with generally mild to moderate gastrointestinal side effects. The study highlights orforglipron’s potential as a convenient oral alternative to injectable GLP-1 agonists, showing promising outcomes in glycemic control and weight management for the specified patient population.
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Jun 21. doi: 10.1056/NEJMoa2505669. Epub ahead of print. PMID: 40544435.

Audio Overview (Google NotebookLM)
(10 minutes 30 seconds)
